Literature DB >> 12955651

Do resident physicians use antibiotics appropriately in treating upper respiratory infections? A survey of 11 programs.

Mohamad G Fakih1, Raymond C Hilu, Ruth T Savoy-Moore, Louis D Saravolatz.   

Abstract

We surveyed resident physicians of 11 primary care programs regarding the management of upper respiratory infections and antibiotic resistance. Although they viewed excess antibiotic use as the most important factor increasing resistance, they had little knowledge regarding antimicrobial resistance and were willing to prescribe antibiotics for common viral illnesses.

Entities:  

Mesh：

Year:  2003        PMID： 12955651     DOI： 10.1086/377503

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  4 in total

1.  Knowledge and misconceptions regarding upper respiratory infections and influenza among urban Hispanic households: need for targeted messaging.

Authors:  Elaine Larson; Yu-Hui Ferng; Jennifer Wong; Maria Alvarez-Cid; Angela Barrett; Maria J Gonzalez; Shuang Wang; Stephen S Morse
Journal:  J Immigr Minor Health       Date:  2008-05-28

2.  On-line virtual patient learning: a pilot study of a new modality in antimicrobial stewardship education for pediatric residents.

Authors:  Amer Alshengeti; Kathryn Slayter; Emily Black; Karina Top
Journal:  BMC Res Notes       Date:  2020-07-14

3.  Improving pediatric emergency department physicians' adherence to clinical practice guidelines on the diagnosis and management of group A beta-hemolytic streptococcal pharyngitis-a cross-sectional study.

Authors:  Ahmed A Alkhazi; Khalid M Alessa; Ahmed M Almutairi; Hamad A Almadi; Abdullah Akkam; Mohammed K Almutairi; Omar A Alhamad; Hadeel S Ghazal
Journal:  Int J Emerg Med       Date:  2018-11-16

Review 4.  Social and professional influences on antimicrobial prescribing for doctors-in-training: a realist review.

Authors:  Chrysanthi Papoutsi; Karen Mattick; Mark Pearson; Nicola Brennan; Simon Briscoe; Geoff Wong
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.